Abstract
Antiresorptive agents, e.g. bisphosphonates or denosumab reduce bone remodeling activity and may be responsible for necrosis also in patients with osteoporosis. In implantology in particular, the relationship between implant survival and bisphosphonate intake has been investigated almost exclusively in recent years. A specific question in the context of the anamnesis and targeted risk evaluation is urgently needed here. In this context, the DGI checklist gives a practical advice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
